IDXG Interpace Biosciences Inc

  1. Stocks
  2. Healthcare
  3. OTC: IDXG

Price (delayed)

$1.02

Market cap

$4.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.38

Enterprise value

$12.5M

Highlights
The net income has surged by 93% year-on-year and by 89% since the previous quarter
IDXG's EPS has surged by 93% year-on-year and by 89% since the previous quarter
The company's debt fell by 9% QoQ but it rose by 3.5% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: https://www.interpacediagnostics.com/
Peers: MOH CNC CI

Key stats

What are the main financial stats of IDXG
Market
Shares outstanding
4.32M
Market cap
$4.41M
Enterprise value
$12.5M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.12
EV/EBIT
N/A
EV/EBITDA
17.53
EV/Sales
0.33
Earnings
Revenue
$38.26M
EBIT
-$595,000
EBITDA
$713,000
Free cash flow
$1.85M
Per share
EPS
-$0.38
Free cash flow per share
$0.43
Book value per share
-$14.53
Revenue per share
$8.86
TBVPS
$3.29
Balance sheet
Total assets
$14.25M
Total liabilities
$30.39M
Debt
$13.12M
Equity
-$62.68M
Working capital
-$886,000
Liquidity
Debt to equity
-0.21
Current ratio
0.93
Quick ratio
0.8
Net debt/EBITDA
11.35
Margins
EBITDA margin
1.9%
Gross margin
59.5%
Net margin
-4.3%
Operating margin
4.3%
Efficiency
Return on assets
-10.6%
Return on equity
N/A
Return on invested capital
-5.4%
Return on capital employed
-30.9%
Return on sales
-1.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IDXG stock price

How has the Interpace Biosciences stock price performed over time
Intraday
-0.97%
1 week
-2.86%
1 month
13.33%
1 year
-34.19%
YTD
-1.92%
QTD
8.51%

Financial performance

How have Interpace Biosciences's revenue and profit performed over time
Revenue
$38.26M
Gross profit
$22.78M
Operating income
$1.63M
Net income
-$1.65M
Gross margin
59.5%
Net margin
-4.3%
The company's operating income has surged by 129% YoY and by 88% QoQ
The company's operating margin has surged by 125% YoY and by 87% QoQ
The company's net margin has surged by 94% YoY and by 89% QoQ
The net income has surged by 93% year-on-year and by 89% since the previous quarter

Growth

What is Interpace Biosciences's growth rate over time

Valuation

What is Interpace Biosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
0.12
EV/EBIT
N/A
EV/EBITDA
17.53
EV/Sales
0.33
IDXG's EPS has surged by 93% year-on-year and by 89% since the previous quarter
The price to sales (P/S) is 83% lower than the 5-year quarterly average of 0.7 but 20% higher than the last 4 quarters average of 0.1
The revenue has grown by 17% YoY and by 2.4% from the previous quarter

Efficiency

How efficient is Interpace Biosciences business performance
IDXG's return on sales has surged by 98% year-on-year and by 96% since the previous quarter
The ROIC has soared by 96% since the previous quarter and by 96% year-on-year
Interpace Biosciences's ROA has soared by 89% from the previous quarter and by 86% YoY

Dividends

What is IDXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IDXG.

Financial health

How did Interpace Biosciences financials performed over time
The company's total assets is 53% lower than its total liabilities
The company's total assets fell by 11% QoQ and by 7% YoY
Interpace Biosciences's current ratio has increased by 8% YoY but it has decreased by 3.1% QoQ
The company's debt is 121% higher than its equity
Interpace Biosciences's debt to equity has increased by 9% QoQ
The company's debt fell by 9% QoQ but it rose by 3.5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.